Form 4: Atossa Therapeutics Director Richard I. Steinhart Acquires Stock Options

Director Richard I. Steinhart reports acquisition of Atossa Therapeutics stock options.

Summary

• Richard I. Steinhart, a director of Atossa Therapeutics, acquired stock options on May 15, 2025.
• The options grant the right to buy 125,000 shares of Atossa Therapeutics common stock at an exercise price of $0.99 per share.
• The options vest quarterly over 12 months following the grant date, contingent upon continued service.
• The options expire on May 15, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued service of the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 12 months is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies in the biotech space, such as Clovis Oncology or Geron Corporation, also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

Atossa Therapeutics, Stock Options, Director, Form 4, Beneficial Ownership, Steinhart, ATOS